No profile data available.
DiaMedica Therapeutics Inc. (DMAC) is a healthcare company in the blood vessel treatment pharmaceuticals industry, based in Minneapolis, United States, with about 35 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$32.77 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $449.20 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases.
DiaMedica Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$449.20 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood vessel treatment pharmaceuticals) include Palvella Therapeutics, Inc. (PVLA), Gossamer Bio, Inc. (GOSS), Tectonic Therapeutic, Inc. (TECX), Tenax Therapeutics, Inc. (TENX).